Logo

Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab

Share this
Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab

Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab

Shots:

  • Veila Bio to receive $30M upfront licensing fee- additional payment on development and commercial milestones plus royalties on sales of product post-launch
  • MTPC to get exclusive rights to develop and commercialize the product in Japan- South Korea- Taiwan- Singapore- Indonesia- Thailand- Malaysia- the Philippines and Vietnam  
  • Inebilizumab is an anti-CD19 mAb that binds to CD19 with high affinity and is currently under investigation for the treatment of neuromyelitis optica spectrum- disorder (NMOSD)

Click here to­ read full press release/ article | Ref: Mitsubishi Tanabe | Image: Twitter



Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions